The Blood Cancer UK–RUNX1 Research Program Project Grant 2027 supports research into preventing blood cancer in people with RUNX1 familial platelet disorder (RUNX1-FPD). The partnership seeks to understand the earliest biological changes preceding malignancy and identify opportunities to predict risk or intervene sooner.
Priority questions include how inherited RUNX1 deficiency affects blood stem cells, mutation accumulation and clonal evolution. Projects may also investigate biomarkers, inflammation, immune mechanisms or approaches supporting future cancer prevention.
Eligibility and Project Criteria
- Lead applicants must be based at an eligible UK institution.
- Junior and senior investigators receive equal consideration.
- International collaborations bringing complementary expertise are encouraged.
- Projects must advance understanding or prevention of malignant progression in RUNX1-FPD.
- Studies using primary human samples should provide a feasible sample-access plan.
- Research must meet the standard Blood Cancer UK Project Grant requirements.
- Discovery and preclinical translational research are eligible; justified small clinical studies may be included.
- Clinical trials, bridging support and biobank infrastructure are outside the standard scheme’s remit.
Funding Details
- Partnership award: Up to £300,000 over three years, as listed by the RUNX1 Research Program.
- Expected support: One jointly funded project.
- Purpose: Research addressing progression from germline RUNX1 deficiency to hematologic malignancy.
- Applicants should confirm the partnership-specific budget when discussing their proposal with the funders.
Deadline
- Application deadline: January 21, 2027, at 3 p.m. UK time.
- Expected outcomes: July 2027.
- Applications require submission through the Blood Cancer UK Grants Portal, allowing time for institutional signatory approval.